Fingerprint
Dive into the research topics of 'Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Floor J. Backes, Debra L. Richardson, Georgia A. McCann, Blair Smith, Ritu Salani, Eric L. Eisenhauer, Jeffrey M. Fowler, Larry J. Copeland, David E. Cohn, David M. O'Malley
Research output: Contribution to journal › Article › peer-review
9
Scopus
citations